What is Sustained Virologic Response (SVR)?
Sustained virologic response (SVR) is the undetectable hepatitis C virus RNA in the blood 12 weeks after completing antiviral treatment, and it represents a virologic cure of hepatitis C infection. 1
Definition and Measurement
SVR is confirmed by undetectable HCV RNA at 12 weeks post-treatment (SVR12), which has replaced the older 24-week standard from the interferon era. 1
SVR12 is tantamount to virologic cure, with fewer than 1% of patients experiencing late relapse after achieving this endpoint. 1
The 12-week timepoint became the standard with direct-acting antiviral (DAA) regimens, which achieve remarkably high cure rates across all HCV genotypes 1-6. 1
Clinical Significance and Durability
Achieving SVR is associated with profound clinical benefits including histologic regression of both necroinflammation and fibrosis, significantly fewer liver-related complications, reduced hepatocellular carcinoma risk, and decreased liver-related mortality. 2
SVR is durable—99.1% of patients who achieve SVR maintain undetectable HCV RNA during long-term follow-up averaging nearly 4 years, and these patients should be considered cured. 3
The risk of late HCV recurrence after confirmed SVR is less than 2% in studies using stringent virological assessment criteria. 4
SVR improves quality of life, cognitive function, physical health, work productivity, and reduces the risk of developing diabetes by addressing HCV-associated insulin resistance. 2, 5
Post-SVR Confirmation Testing
A routine confirmation test at 48 weeks post-treatment is recommended by the American Gastroenterological Association, though routine testing beyond 48 weeks is not supported by evidence. 1
Patients with ongoing risk factors for reinfection (such as active injection drug use) require indefinite periodic HCV RNA testing even after achieving SVR. 6
Important Clinical Caveat
While SVR represents cure of the viral infection, patients with advanced fibrosis (stage F3) or cirrhosis at the time of treatment still require indefinite semi-annual hepatocellular carcinoma surveillance with liver imaging ± alpha-fetoprotein, as the cancer risk persists despite viral clearance. 1, 6 This is a critical distinction—SVR cures the infection but does not eliminate all long-term complications in patients with pre-existing advanced liver disease.